REPH - Recro Pharma, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
11.45
+0.16 (+1.46%)
As of 11:20AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close11.29
Open10.80
Bid11.43 x 800
Ask11.48 x 2200
Day's Range11.34 - 11.59
52 Week Range5.53 - 11.85
Volume22,913
Avg. Volume203,534
Market Cap254.084M
Beta (3Y Monthly)0.58
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire

    Recro Pharma Reports Second Quarter 2019 Financial Results

    Record Results and Raising Guidance Announces Plan to Spin Acute Care Company to Host Conference Call Today at 8:00 AM ET MALVERN, Pa., Aug. 08, 2019 -- Recro Pharma, Inc..

  • GlobeNewswire

    Recro Pharma to Present at Upcoming Investor Conferences

    Live and archived webcasts of the presentations will be available on the Presentations page of the company’s website at http://recropharma.com. Recro Pharma is a specialty pharma company that operates through two business divisions, a revenue-generating contract development and manufacturing, or CDMO, division, located in Gainesville, GA and an Acute Care division primarily focused on products for the hospital and other acute care settings.

  • GlobeNewswire

    Recro Pharma Reports First Quarter 2019 Financial Results

    MALVERN, Philadelphia, May 10, 2019 -- Recro Pharma, Inc. (NASDAQ:REPH), a pharma company with a high-performing, revenue generating contract development and manufacturing.

  • GlobeNewswire

    Recro Pharma to Report First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 10, 2019

    Recro Pharma, Inc. (REPH) today announced that it will report first quarter financial results on Friday, May 10, 2019. Recro's management team will host a conference call and audio webcast at 8:00 a.m. ET on Friday, May 10, 2019 to discuss the financial results and recent operational highlights. To access the conference call, please dial (844) 243-4691 (local) or (225) 283-0379 (international) at least 10 minutes prior to the start time and refer to conference ID 8294704.

  • GlobeNewswire

    Recro Pharma Announces Six-Year Extension of License and Supply Agreement Between Teva and Recro Gainesville

    Recro Pharma, Inc. (REPH), a specialty pharmaceutical company with a high-performing revenue generating contract development and manufacturing (CDMO) division, today announced that Recro Gainesville LLC, its CDMO division, has amended its existing license and supply agreement with Teva Pharmaceutical to extend the agreement for six years, effective January 1, 2019.

  • GlobeNewswire

    Recro Pharma Announces Presentation of New Meta-Analysis for IV Meloxicam at the 44th Annual Regional Anesthesiology and Acute Pain Medicine Meeting

    Recro Pharma, Inc. (REPH), a specialty pharmaceutical company with a high-performing revenue generating contract development and manufacturing (CDMO) segment, today announced a moderated poster presentation highlighting new intravenous (IV) meloxicam data at the 44th Annual Regional Anesthesiology and Acute Pain Medicine Meeting, hosted by the American Society of Regional Anesthesia and Pain Medicine, taking place April 11-13, 2019, in Las Vegas. In this study, the researchers conducted a network meta-analysis (NMA) assessing the safety and efficacy of IV meloxicam relative to other IV non-opioid analgesics for moderate to severe pain. The analysis was conducted by comparing Recro Pharma’s IV meloxicam data to 17 randomized controlled clinical trials evaluating several non-opioid analgesics, including acetaminophen, ketorolac, placebo combined with a non-opioid and placebo combined with an opioid, across three procedure categories: abdominal, bunionectomy and orthopedic.

  • GlobeNewswire

    Recro Pharma Restructures Acute Care Segment While Continuing To Execute on Strong CDMO Segment Performance

    Recro Pharma, Inc. (REPH), a revenue generating specialty pharmaceutical company with a high-performing contract development and manufacturing (CDMO) Segment, today announced an initiative that will reduce the operating expenses of its Acute Care Segment, including a reduction in staff of approximately 50 employees. Some Acute Care Segment employees engaged in efforts to select a partner for and in obtaining FDA approval of (IV) meloxicam were retained.  This initiative is expected to significantly lower operating expenses following receipt of a second Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) Office of Drug Evaluation II regarding its New Drug Application (NDA).

  • GlobeNewswire

    Recro Pharma Appoints Arnaud Ajdler to Its Board of Directors

    Recro Pharma, Inc. (REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care settings, today announced the appointment of Arnaud Ajdler to the Company’s Board of Directors. Mr. Ajdler, managing partner of Engine Capital, L.P., brings over 15 years of finance and corporate governance experience to Recro’s Board. “Arnaud brings to Recro significant investment and corporate governance experience gained from his participation on multiple public company boards,” said Gerri Henwood, President and Chief Executive Officer of Recro Pharma.

  • GlobeNewswire

    Recro Pharma Receives Complete Response Letter from the FDA for Intravenous Meloxicam

    Recro Pharma, Inc. (REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care settings, today announced it has received a second Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) Office of Drug Evaluation II regarding their New Drug Application (NDA) seeking approval for intravenous (IV) meloxicam for the management of moderate to severe pain. The FDA’s comments in the CRL focused on onset and duration of IV meloxicam, noting that the delayed onset fails to meet the prescriber expectations for intravenous (IV) drugs.  The  CRL also cited regulatory concerns about the role of IV meloxicam as a monotherapy in acute pain, as well as how it would meet patient and prescriber needs in that setting, given the FDA's interpretation of the clinical trials data.  The company strongly disagrees with FDA's interpretation and its views on the clinical utility of IV meloxicam in the acute pain setting.  The FDA did not identify any CMC issues in this CRL.

  • GlobeNewswire

    Recro Pharma to Host Educational Symposium on Pain Management Options in Total Joint Replacements at the American Academy of Orthopaedic Surgeons 2019 Annual Meeting

    Recro Pharma, Inc. (REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care settings, today announced an Industry ‘Lunch and Learn’ Session at the upcoming American Academy of Orthopaedic Surgeons (AAOS) 2019 Annual Meeting, being held March 12-16, 2019 in Las Vegas, NV at the Venetian/Sands Expo. The Company is hosting this event on Wednesday, March 13 from 12:40 to 1:25 p.m. PT, which will be located on Level 3 in Room 3103. Recro Pharma is a specialty pharmaceutical company that operates through two business divisions, an Acute Care, hospital product division and a revenue-generating contract development and manufacturing, or CDMO, division, located in Gainesville, GA.

  • GlobeNewswire

    Recro Pharma Obtains $40.5 Million of Non-Dilutive Capital Through Expanded Credit Facility

    Recro Pharma, Inc. (REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care settings, today announced that it has closed on an amended and expanded $125 million credit facility with investment funds managed by Athyrium Capital Management, LP (Athyrium), a leading healthcare-focused investment firm.  The increased financial flexibility created by this non-dilutive funding will strengthen the Company’s balance sheet and support the Company’s plans to commercialize its lead drug candidate, intravenous (IV) meloxicam, which is currently under review by the U.S. Food and Drug Administration (FDA), while the Company is awaiting its assigned PDUFA goal date of March 24, 2019.

  • GlobeNewswire

    Recro Pharma Announces Publication of Phase III IV Meloxicam Clinical Safety and Opioid Use Data in the Journal Clinical Pharmacology in Drug Development

    MALVERN, Pa., Feb. 25, 2019 -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute.

  • GlobeNewswire

    Recro Pharma Announces New IV Meloxicam Data Publication in the Journal Regional Anesthesia & Pain Medicine

    Recro Pharma, Inc. (REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care settings, today announced the publication of new intravenous (IV) meloxicam data.  The article, titled “Meloxicam intravenous for the treatment of moderate to severe acute pain: a pooled analysis of safety and opioid-reducing effects,” was published online in Regional Anesthesia & Pain Medicine.  A New Drug Application (NDA) for IV meloxicam is currently under review by the U.S. Food and Drug Administration (FDA) and the Company is currently awaiting its assigned PDUFA goal date of March 24, 2019. The published data describe the pooled safety across a total of seven clinical studies (three Phase III and four Phase II), where IV meloxicam (5-15mg, 30mg or 60 mg) was evaluated in patients following several types of surgeries, including dental impaction surgery, open abdominal hysterectomy, abdominal laparoscopic surgery, bunionectomy, and abdominoplasty, among others.  In this pooled analysis, IV meloxicam was generally well-tolerated, with the incidence of TEAEs occurring in a lower percentage of IV meloxicam-treated patients than in placebo-treated patients (47% versus 57%, respectively).  The most commonly reported TEAEs across all treatment groups were nausea, headache, vomiting and dizziness.  Notably, TEAE incidence was generally similar between the overall study populations and older patients ( 65 years) with impaired renal function.  There were no drug-related deaths for patients treated with IV meloxicam.

  • GlobeNewswire

    Recro Pharma Reports Financial Results for the Fourth Quarter and Year End 2018

    March 24, 2019 PDUFA Goal Date for IV Meloxicam Record CDMO Performance; 2018 Revenues of $77.3 Million Company to Host Conference Call Today at 8:00 AM ET MALVERN, Pa., Feb..

  • ACCESSWIRE

    Recro Pharma, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 19, 2019 / Recro Pharma, Inc. (NASDAQ: REPH ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 19, 2019 at 8:00 ...

  • GlobeNewswire

    Recro Pharma to Report Fourth Quarter and Year End 2018 Financial Results and Host Conference Call and Webcast on February 19, 2019

    Recro Pharma, Inc. (REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced that it will report fourth quarter and year end financial results on Tuesday, February 19, 2019. Recro's management team will host a conference call and audio webcast at 8:00 a.m. ET on Tuesday, February 19, 2019 to discuss the financial results and recent operational highlights. A live audio webcast of the call will be available under "Events" in the Investor section of the Company's website, https://ir.recropharma.com/events.

  • GlobeNewswire

    Recro Pharma Announces Five-Year Manufacturing and Supply Agreement Between Novartis and Recro Gainesville

    Recro Pharma, Inc. (REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care settings, today announced that Recro Gainesville LLC, its contract development and manufacturing (CDMO) division, has entered into a five-year manufacturing and supply agreement with Novartis Pharma AG (“2019 Novartis Agreement”), effective January 1, 2019. Under the terms of the agreement, Recro Gainesville will continue to be the exclusive global supplier to Novartis of Ritalin LA and Focalin XR capsules through 2023.  The prior Novartis supply contracts for Ritalin LA and Focalin XR were set to expire in late 2019 and mid-2020, respectively, and provided for two revenue components, product manufacturing revenue and royalty revenue.

  • GlobeNewswire

    Recro Pharma Amends Athyrium Credit Facility

    Recro Pharma, Inc. (REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care settings, today announced an amendment to its existing credit facility with Athyrium Capital Management, LP (Athyrium), a leading healthcare-focused investment firm. A New Drug Application (NDA) for Recro Pharma’s lead candidate, intravenous (IV) meloxicam, is currently under review by the U.S. Food and Drug Administration (FDA), and the Company is awaiting its assigned PDUFA goal date of March 24, 2019. “This amended credit facility reinstates access to $40 million in debt funding, providing Recro Pharma with greater financial flexibility, and importantly, provides near-term capital to pay certain of the milestone payments due to Alkermes under our recently amended global licensing agreement for IV meloxicam and contributes toward our commercial launch efforts of IV meloxicam,” said Gerri Henwood, Recro Pharma's President and Chief Executive Officer.

  • GlobeNewswire

    Recro Pharma Amends IV Meloxicam License Agreement with Alkermes

    Recro Pharma, Inc. (REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced an amendment to its global licensing agreement with Alkermes Pharma Ireland Limited (Alkermes) concerning the milestone payments for intravenous (IV) meloxicam.  A New Drug Application (NDA) for IV meloxicam is currently under review by the U.S. Food and Drug Administration (FDA) and the Company is currently awaiting its assigned PDUFA goal date of March 24, 2019. Under the prior agreement as amended, Recro Pharma owed Alkermes a milestone payment of $45 million upon approval of IV meloxicam by the FDA.  This newly executed amendment provides that Recro Pharma will now pay to Alkermes $5 million within 30 calendar days following the amendment effective date, $5 million in April 2019, and $5 million within 180 days following approval of IV meloxicam by the FDA.  Recro Pharma will then pay to Alkermes a total of $45 million in seven equal annual payments of $6.4 million each, commencing upon the first anniversary following FDA approval.

  • GlobeNewswire

    Recro Pharma Announces Presentation of New Data Demonstrating IV Meloxicam’s Effect on Platelet Function at the 72nd PostGraduate Assembly in Anesthesiology

    Recro Pharma, Inc. (REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced a poster presentation highlighting intravenous (IV) meloxicam’s effect on platelet function at the 72nd PostGraduate Assembly in Anesthesiology (PGA72), sponsored by the New York State Society of Anesthesiologists (NYSSA), taking place December 7-11, 2018, in New York City. In the CEPI reagent analysis, a significant treatment effect was observed for changes in CT (p=0.0441).  No significant difference was observed in CT for the IV meloxicam treated samples versus the untreated control at any of the evaluated concentrations (p≥0.5400).  When compared to untreated control, the ketorolac treated sample CT values were significantly prolonged in both the 2.5mcg/mL and the 5mcg/mL concentrations (p≤0.0257).  All IV meloxicam concentration levels had a significantly shorter CT compared to the 2.5mcg/mL ketorolac concentration (p

  • GlobeNewswire

    Detailed Research: Economic Perspectives on StarTek, Plantronics, Akoustis Technologies, Genie Energy, Recro Pharma, and BIO-key International — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Nov. 16, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire

    Recro Pharma Announces Publication of Phase II IV Meloxicam Abdominal Hysterectomy Data in Anesthesia & Analgesia

    Recro Pharma, Inc. (REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced the publication of previously reported Phase II clinical data for intravenous (IV) meloxicam for the treatment of pain following open abdominal hysterectomy. The article, titled “Analgesic Efficacy and Safety of Intravenous Meloxicam in Subjects with Moderate-to-Severe Pain After Open Abdominal Hysterectomy: A Phase 2 Randomized Clinical Trial,” was published online in Anesthesia & Analgesia. “These results from our Phase II trial evaluating IV meloxicam for the management of moderate to severe pain following abdominal hysterectomy surgery highlight IV meloxicam’s analgesic effect, coupled with a favorable safety and tolerability profile, in a soft tissue surgical model,” said Stewart McCallum, M.D., Chief Medical Officer of Recro Pharma.

  • GlobeNewswire

    Recro Pharma to Participate in Upcoming Investor Conferences

    A live and archived webcast of the Piper Jaffray presentation will be available on the Events page of the Company’s website www.recropharma.com. Recro Pharma is a specialty pharmaceutical company that operates through two business divisions, an Acute Care, hospital product division and a revenue-generating contract development and manufacturing, or CDMO division, located in Gainesville, GA.

  • GlobeNewswire

    Recro Pharma Reports Third Quarter 2018 Financial Results Raising Guidance for CDMO business for 2018

    Company to Host Conference Call Today at 8:00 AM ET MALVERN, Pa., Nov. 07, 2018 -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company.

  • GlobeNewswire

    Recro Pharma to Report Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 7, 2018

    Recro Pharma, Inc. (REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced that it will report third quarter financial results on Wednesday, November 7, 2018. Recro's management team will host a conference call and audio webcast at 8:00 a.m. ET on Wednesday, November 7, 2018 to discuss the financial results and recent operational highlights. A live audio webcast of the call will be available under "Events" in the Investor section of the Company's website, https://ir.recropharma.com/events.